StockData

Amarin vs Zevra Therapeutics

AMRN and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMRN and ZVRA compare

Amarin is the larger company, worth 9.1 times as much as Zevra Therapeutics ($5.0B against $549M).

Zevra Therapeutics grew revenue faster over the last twelve months (119% versus −22.3% for Amarin).

Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −10.9% at Amarin.

Zevra Therapeutics scores higher on the StockData Score (15 against 10 for Amarin), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMRNZVRA
Size and price
Market cap$5.0B$549M
Share price$11.31$9.25
Change, 1 year−30.5%0.22%
Change, 5 years−84.5%14.9%
Beta (5Y)0.731.18
Employees8061
StockData Score
Total score1015 (better)
Valuation score03 (better)
Growth score13 (better)
Performance score33
Health score66
Dividend score00
Valuation
P/E–9.9×
P/S28.4×4.0× (better)
P/B11.3×2.5× (better)
EV/EBITDA–3.9×
P/FCF–16.8×
FCF yield–5.9%
Fair value$7.00$23.75
Margin of safety−61.5%61.0% (better)
Growth
Revenue growth (TTM)−22.3%119% (better)
Revenue growth, 5Y average−19.0%51.6% (better)
Net income growth (TTM)–2104%
Profitability
Gross margin40.9%95.5% (better)
Operating margin−18.2%60.5% (better)
Net margin−10.9%42.8% (better)
FCF margin–24.0%
Return on equity−4.2%34.8% (better)
Return on invested capital−17.3%–
Financial health
Debt / equity0.000.00
Net debt / EBITDA–−2.64
Interest coverage–14.4×
Current ratio3.505.17 (better)
Altman Z-score12.95 (better)4.29
Piotroski F-score7 (better)6
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.0%78.5%
Held by insiders7.0%1.2%
Insider net buying, 12 months–−$2.5M
Short interest, % of float–11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.